Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty fi
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Contin
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
02:34am, Tuesday, 17'th Mar 2026
Executives from Esperion Therapeutics (NASDAQ: ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citiz
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterol
Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25
01:44am, Monday, 16'th Mar 2026
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, Mar
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
12:50pm, Wednesday, 11'th Mar 2026
Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
10:40am, Tuesday, 10'th Mar 2026
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
08:16am, Tuesday, 10'th Mar 2026
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
06:00am, Tuesday, 10'th Mar 2026
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
11:40am, Wednesday, 04'th Mar 2026
Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
05:22pm, Tuesday, 03'rd Mar 2026
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
Esperion Acquires Enbumyst Maker Corstasis
08:25am, Tuesday, 03'rd Mar 2026
Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst.
– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Comme
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?
11:01am, Tuesday, 24'th Feb 2026
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR
03:21am, Friday, 20'th Feb 2026
Principal Financial Group Inc. lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 51.7% during the undefined quarter, according to the company in its most recent disclosu
